Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amylyx

Amylyx?uq=kzBhZRuG
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Early Stage VC LATEST DEAL TYPE (In Progress)
$1.83M LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's therapeutics are a combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 210 Broadway
  • Suite 201
  • Cambridge, MA 02139
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Amylyx’s full profile, request a free trial.

Amylyx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 04-Aug-2017 $1.83M 00.000 In Progress Generating Revenue
3. Early Stage VC (Series A) 22-Aug-2016 000 00.00 0000 Completed Generating Revenue
2. Grant 20-Jul-2016 $3.56M $1.3M Completed Generating Revenue
1. Early Stage VC $1.3M $1.3M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Amylyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Amylyx Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
ALS Investment Fund Venture Capital Minority 000 0000 000000 0
Henri Termeer Angel (individual) Minority 000 0000 000000 0
Morningside Group PE/Buyout Minority 000 0000 000000 0
ALS Finding a Cure Foundation Limited Partner Minority 000 0000 000000 0
Cure Alzheimer's Fund Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Amylyx Executive Team (3)

Name Title Board
Seat
Contact
Info
Joshua Cohen Co-Founder, Chief Executive Officer and Board Member
Justin Klee Co-Founder, President and Board Member
Kent Leslie Vice President of Research

Amylyx Board Members (7)

Name Representing Role Since Contact
Info
Alan Walts Ph.D Self Board Observer 000 0000
Felix von Coerper ALS Investment Fund Board Member 000 0000
George Milne Amylyx Board Member 000 0000
Henri Termeer Ph.D Self Board Observer & Advisor 000 0000
Isaac Cheng MD Morningside Group Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »